Skip to main content

News

Sydney skin cancer patients join the EPIC-Skin study as they undergo first treatments with OncoBeta’s Rhenium-SCT

Garching, Munich. Germany – OncoBeta® GmbH has announced its first Sydney-based patients were treated with Rhenium-SCT® as part of the global phase IV…

Read more

Sydney skin cancer patients join the EPIC-Skin study as they undergo first treatments with OncoBeta's Rhenium-SCT

Garching, Munich. Germany – OncoBeta® GmbH has announced its first Sydney-based patients were treated with Rhenium-SCT® as part of the global phase IV…

Read more

EPIC-Skin study welcomes world-first skin cancer patients treated with OncoBeta’s Rhenium-SCT

Garching,Munich.Germany – OncoBeta® GmbH has today announced a world-first from Australia, with the first patients treated with Rhenium-SCT® as part…

Read more

EPIC-Skin study welcomes world-first skin cancer patients treated with OncoBeta’s Rhenium-SCT

Garching,Munich.Germany – OncoBeta® GmbH has today announced a world-first from Australia, with the first patients treated with Rhenium-SCT® as part…

Read more

EPIC-Skin study welcomes world-first skin cancer patients treated with OncoBeta’s Rhenium-SCT

Garching,Munich.Germany – OncoBeta® GmbH has today announced a world-first from Australia, with the first patients treated with Rhenium-SCT® as part…

Read more
OncoBeta International Registry

First patients registered into OncoBeta’s International Registry for Non-Melanoma Skin Cancer treatments

The International Registry is an observational, multicentre, non-interventional program for patients diagnosed with non-melanoma skin cancer (NMSC),…

Read more
EPIC Skin Study Ethics Approval

OncoBeta receives ethics approval for EPIC-Skin study to evaluate Rhenium-SCT in Australia

21st December 2021

Garching b. Munich, Germany – OncoBeta® GmbH, a medical device company specialized in innovative epidermal radioisotope therapies…

Read more
International registry launch

OncoBeta launches International Registry for Non-Melanoma Skin Cancer

23rd November 2021

Garching near Munich, Germany – OncoBeta® GmbH  announces  the  launch  of  a  first-of-its- kind International Registry for NMSC.…

Read more
Skin Cancer Patients Now Have Greater Access to Rhenium-188 in South Africa

South African non-melanoma skin cancer patients now have greater access in the area of Johannesburg to innovative non-invasive treatment Rhenium-SCT®

Lethabong, South Africa, 16 November 2021: Today OncoBeta® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies…

Read more
First patients treated in Austria

First non-melanoma skin cancer patients treated with the Rhenium-SCT® in Austria

Vienna, Austria, 28 October 2021: OncoBeta® GmbH, a medical device company specialized in innovative epidermal radioisotope therapies for non-melanoma…

Read more